Nesiritide与失代偿心力衰竭治疗  

Nesiritide Therapy in Decompensated Heart Failure

作　　者：王鑫[1] 李文华[1] 朱艳利[1] 

机构地区：[1]山东大学山东省立医院老年病科,山东济南250021

出　　处：《心血管病学进展》2006年第4期514-518,共5页Advances in Cardiovascular Diseases

摘　　要：Nesiritide是重组人脑钠肽,国外多项前瞻性临床研究证实它能较传统静脉治疗药物短期内迅速改善急性失代偿心力衰竭患者的血流动力学状况和症状,从而成为现代心力衰竭治疗的一种新药。但汇总分析调查其安全性发现,可增加短期病死率和肾功能损害的危险性,提示重组人脑钠肽的短期高效并不能代替长期安全性。是否能成为失代偿心力衰竭治疗新的一线用药,需要以病死率为终点事件的大规模前瞻性随机双盲对照研究提供循证医学依据。Nesiritide is a drug agent for decompensated heart failure therapy. Nesiritide is a recombinant form of human brain natriuretic peptide （rhBNP）. Several prospective clinical studies have confirmed that rhBNP is able to improve hemodynamics and symptoms more quickly than other traditional medication in patients with decompensated heart failure. Meta-analysis investigations into the safety of Nesiritide have raised the concern that rhBNP is associated with increasing risk of shorterm mortality and worsening renal function. The shortterm effects of nesiritide may not be sufficient to ensure patients＇long-term safety. A prospective mortality trial based on evidence is required to determine whether it is qualified to be a first-line drug agent in decompensated heart failure.

关 键 词：心力衰竭 脑钠肽 治疗 

分 类 号：R541.6[医药卫生—心血管疾病]